Literature DB >> 12085323

Bactericidal group IIA phospholipase A2 in serum of patients with bacterial infections.

Juha O Grönroos1, Veli J O Laine, Timo J Nevalainen.   

Abstract

Group IIA phospholipase A2 (PLA2-IIA) is a newly recognized antibacterial acute phase protein. The concentration of PLA2-IIA increases up to 500-fold in the blood plasma of patients with severe acute diseases, compared with healthy persons. Despite numerous studies, the exact roles of this enzyme in human diseases are unknown. This study investigated the antibacterial properties of PLA2-IIA in human acute phase serum. PLA2-IIA in serum samples of patients with bacterial infections was capable of killing 90% of Staphylococcus aureus and 99% of Listeria monocytogenes in vitro after incubation for 2 h. At concentrations found in normal human serum, PLA2-IIA killed 90% of L. monocytogenes but did not kill S. aureus or Escherichia coli. The bactericidal effects of acute phase and normal human serum were abolished after depletion of PLA2-IIA by immunoadsorption.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12085323     DOI: 10.1086/340821

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Multiple roles of phospholipase A2 during lung infection and inflammation.

Authors:  Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

Review 2.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

3.  Antimalarial Activity of Human Group IIA Secreted Phospholipase A2 in Relation to Enzymatic Hydrolysis of Oxidized Lipoproteins.

Authors:  Mélanie Dacheux; Véronique Sinou; Christine Payré; Louise Jeammet; Daniel Parzy; Philippe Grellier; Christiane Deregnaucourt; Gérard Lambeau
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

Review 4.  Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease.

Authors:  Nhat D Quach; Robert D Arnold; Brian S Cummings
Journal:  Biochem Pharmacol       Date:  2014-06-04       Impact factor: 5.858

5.  Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery.

Authors:  Masaaki Ogawa; Nobuhiro Sato; Shigeatsu Endo; Masahiro Kojika; Yasunori Yaegashi; Yusuke Kimura; Kenichiro Ikeda; Takeshi Iwaya
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 6.  Molecular determinants of bacterial sensitivity and resistance to mammalian Group IIA phospholipase A2.

Authors:  Jerrold P Weiss
Journal:  Biochim Biophys Acta       Date:  2015-06-14

7.  Group IIA-Secreted Phospholipase A2 in Human Serum Kills Commensal but Not Clinical Enterococcus faecium Isolates.

Authors:  Fernanda L Paganelli; Helen L Leavis; Samantha He; Nina M van Sorge; Christine Payré; Gérard Lambeau; Rob J L Willems; Suzan H M Rooijakkers
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

8.  The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.

Authors:  Tuulia Avoranta; Jari Sundström; Eija Korkeila; Kari Syrjänen; Seppo Pyrhönen; Jukka Laine
Journal:  Virchows Arch       Date:  2010-10-12       Impact factor: 4.064

9.  Secreted phospholipase A2 is increased in meconium-stained amniotic fluid of term gestations: potential implications for the genesis of meconium aspiration syndrome.

Authors:  Roberto Romero; Bo Hyun Yoon; Piya Chaemsaithong; Josef Cortez; Chan-Wook Park; Rogelio Gonzalez; Ernesto Behnke; Sonia S Hassan; Francesca Gotsch; Lami Yeo; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-01-06

10.  The phospholipid-repair system LplT/Aas in Gram-negative bacteria protects the bacterial membrane envelope from host phospholipase A2 attack.

Authors:  Yibin Lin; Mikhail Bogdanov; Shuo Lu; Ziqiang Guan; William Margolin; Jerrold Weiss; Lei Zheng
Journal:  J Biol Chem       Date:  2018-01-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.